Business Summary
|
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company that designs, optimizes and develops novel drugs that block enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-based drug design. The Company’s product candidate, forodesine HCl, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). An oral formulation of the compound is in a Phase IIb trial for patients with Cutaneous T-cell Lymphoma (CTCL). Additionally, forodesine HCl is being studied in a Phase II trial with an oral formulation in Chronic Lymphocytic Leukemia (CLL). Its another drug candidate, peramivir, is an inhibitor of influenza neuraminidase.
| | (Source: 10-K)
|
|
|
